A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

NCT02773368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec/liraglutide
DRUG: insulin glargine

Sponsor

Novo Nordisk A/S